Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 1,450,000 shares, an increase of 27.2% from the June 30th total of 1,140,000 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average trading volume of 246,600 shares, the days-to-cover ratio is currently 5.9 days.
Centessa Pharmaceuticals Stock Performance
Shares of CNTA stock traded up $0.07 during mid-day trading on Tuesday, hitting $10.72. The company’s stock had a trading volume of 1,352 shares, compared to its average volume of 306,212. The company’s fifty day simple moving average is $9.14 and its 200-day simple moving average is $9.61. Centessa Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $12.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.37 and a current ratio of 10.37.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.62 earnings per share for the current year.
Institutional Trading of Centessa Pharmaceuticals
Analyst Ratings Changes
Several equities research analysts recently weighed in on CNTA shares. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, July 18th. They set an “outperform” rating and a $14.00 price objective on the stock. Morgan Stanley lifted their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, June 21st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.
Get Our Latest Stock Analysis on CNTA
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Read More
- Five stocks we like better than Centessa Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Why SoFi Stock is an Unmissable Growth Opportunity
- Best Aerospace Stocks Investing
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
- The 3 Best Blue-Chip Stocks to Buy Now
- Should You Invest in Bonds? Here’s What to Know
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.